{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:34:12Z","timestamp":1794008052256,"version":"4.8.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s13346-023-01380-1","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T09:02:24Z","timestamp":1687338144000},"page":"3192-3203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Poly(ethylene glycol)-b-poly(epsilon-caprolactone) nanoparticles as a platform for the improved oral delivery of cannabidiol"],"prefix":"10.1007","volume":"13","author":[{"given":"Inbar","family":"Shreiber-Livne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liron","family":"Sulimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Shapira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiri","family":"Procaccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Meiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Sosnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"1380_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1515\/jbcpp-2016-0045","volume":"9","author":"NM Kogan","year":"2007","unstructured":"Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neurosci. 2007;9:413\u201330. https:\/\/doi.org\/10.1515\/jbcpp-2016-0045.","journal-title":"Dialogues Clin Neurosci"},{"key":"1380_CR2","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/ptr.4781","volume":"27","author":"G Esposito","year":"2013","unstructured":"Esposito G, De Filippis D, Cirillo C, Iuvone T, Capoccia E, Scuderi C, Steardo A, Cuomo R, Steardo L. Cannabidiol in inflammatory bowel diseases: a brief overview. Phytoher Res. 2013;27:633\u20136. https:\/\/doi.org\/10.1002\/ptr.4781.","journal-title":"Phytoher Res."},{"key":"1380_CR3","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/j.1476-5381.2010.00791.x","volume":"160","author":"JM Jamontt","year":"2010","unstructured":"Jamontt JM, Molleman A, Pertwee RG, Parsons ME. The effects of \u0394 9-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. Br J Pharmacol. 2010;160:712\u201323. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00791.x.","journal-title":"Br J Pharmacol"},{"key":"1380_CR4","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/cam4.1312","volume":"7","author":"P \u015aledzi\u0144ski","year":"2018","unstructured":"\u015aledzi\u0144ski P, Zeyland J, S\u0142omski R, Nowak A. The current state and future perspectives of cannabinoids in cancer biology. Cancer Med. 2018;7:765\u201375. https:\/\/doi.org\/10.1002\/cam4.1312.","journal-title":"Cancer Med"},{"key":"1380_CR5","doi-asserted-by":"publisher","unstructured":"Perucca E. Cannabinoids in the treatment of epilepsy: hard evidence at last? Epilepsy Res. 2017;7:61\u201376. https:\/\/doi.org\/10.14581\/jer.17012.","DOI":"10.14581\/jer.17012"},{"key":"1380_CR6","doi-asserted-by":"publisher","unstructured":"ElSohly M, Gul W. Handbook of Cannabis. (Roger G. Pertwee, ed.). Oxford University Press; 2014. https:\/\/doi.org\/10.1093\/acprof:oso\/9780199662685.001.0001.","DOI":"10.1093\/acprof:oso\/9780199662685.001.0001"},{"key":"1380_CR7","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1039\/C6NP00074F","volume":"33","author":"LO Hanu\u0161","year":"2016","unstructured":"Hanu\u0161 LO, Meyer SM, Mu\u00f1oz E, Taglialatela-Scafati O, Appendino G. Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 2016;33:1357\u201392. https:\/\/doi.org\/10.1039\/C6NP00074F.","journal-title":"Nat Prod Rep"},{"issue":"11 SUPPL.","key":"1380_CR8","doi-asserted-by":"publisher","first-page":"11S","DOI":"10.1002\/j.1552-4604.2002.tb05998.x","volume":"42","author":"R Mechoulam","year":"2002","unstructured":"Mechoulam R, Parker LA, Gallily R. Cannabidiol: An overview of some pharmacological aspects. J Clin Pharmacol. 2002;42(11 SUPPL.):11S-19S. https:\/\/doi.org\/10.1002\/j.1552-4604.2002.tb05998.x.","journal-title":"J Clin Pharmacol"},{"key":"1380_CR9","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ptr.2625","volume":"23","author":"C Scuderi","year":"2009","unstructured":"Scuderi C, De Filippis D, Iuvone T, Blasio A, Steardo A, Esposito G. Cannabidiol in medicine: A review of its therapeutic potential in CNS disorders. Phytother Res. 2009;23:597\u2013602. https:\/\/doi.org\/10.1002\/ptr.2625.","journal-title":"Phytother Res"},{"key":"1380_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01365","author":"SA Millar","year":"2018","unstructured":"Millar SA, Stone NL, Yates AS, O\u2019Sullivan SE. A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 2018. https:\/\/doi.org\/10.3389\/fphar.2018.01365.","journal-title":"Front Pharmacol"},{"key":"1380_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40429-020-00326-8","volume":"7","author":"DJ Sholler","year":"2020","unstructured":"Sholler DJ, Schoene L, Spindle TR. Therapeutic efficacy of cannabidiol (CBD): a review of the evidence from clinical trials and human laboratory studies. Curr Addict Rep. 2020;7:405\u201312. https:\/\/doi.org\/10.1007\/s40429-020-00326-8.","journal-title":"Curr Addict Rep"},{"key":"1380_CR12","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/epi.16597","volume":"61","author":"R Odi","year":"2020","unstructured":"Odi R, Bibi D, Wager T, Bialer M. A perspective on the physicochemical and biopharmaceutic properties of marketed antiseizure drugs\u2014From phenobarbital to cenobamate and beyond. Epilepsia. 2020;61:1543\u201352. https:\/\/doi.org\/10.1111\/epi.16597.","journal-title":"Epilepsia"},{"key":"1380_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13122142","author":"A Sosnik","year":"2021","unstructured":"Sosnik A, Shabo RB, Halamish HM. Cannabidiol-loaded mixed polymeric micelles of chitosan\/poly(vinyl alcohol) and poly(methyl methacrylate) for trans-corneal delivery. Pharmaceutics. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13122142.","journal-title":"Pharmaceutics"},{"key":"1380_CR14","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1691\/ph.2020.0076","volume":"75","author":"RA Vlad","year":"2020","unstructured":"Vlad RA, Hancu G, Ciurba A, Antonoaea P, R\u00e9dai EM, Todoran N, Silasi O, Muntean DL. Cannabidiol - therapeutic and legal aspects. Pharmazie. 2020;75:463\u20139. https:\/\/doi.org\/10.1691\/ph.2020.0076.","journal-title":"Pharmazie"},{"key":"1380_CR15","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s40262-020-00931-w","volume":"59","author":"V Franco","year":"2020","unstructured":"Franco V, Gershkovich P, Perucca E, Bialer M. The interplay between liver first-pass effect and lymphatic absorption of cannabidiol and its implications for cannabidiol oral formulations. Clin Pharmacokinet. 2020;59:1493\u2013500. https:\/\/doi.org\/10.1007\/s40262-020-00931-w.","journal-title":"Clin Pharmacokinet"},{"key":"1380_CR16","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/bcp.13710","volume":"84","author":"CJ Lucas","year":"2018","unstructured":"Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84:2477\u201382. https:\/\/doi.org\/10.1111\/bcp.13710.","journal-title":"Br J Clin Pharmacol"},{"key":"1380_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.106058","author":"LY Kok","year":"2022","unstructured":"Kok LY, Bannigan P, Sanaee F, Evans JC, Dunne M, Regenold M, Ahmed L, Dubins D, Allen C. Development and pharmacokinetic evaluation of a self-nanoemulsifying drug delivery system for the oral delivery of cannabidiol. Eur J Pharm Sci. 2022. https:\/\/doi.org\/10.1016\/j.ejps.2021.106058.","journal-title":"Eur J Pharm Sci"},{"key":"1380_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejps.2017.07.003","volume":"109","author":"I Cherniakov","year":"2017","unstructured":"Cherniakov I, Izgelov D, Domb AJ, Hoffman A. The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model. Eur J Pharm Sci. 2017;109:21\u201330. https:\/\/doi.org\/10.1016\/j.ejps.2017.07.003.","journal-title":"Eur J Pharm Sci"},{"key":"1380_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejpb.2020.06.021","volume":"154","author":"D Izgelov","year":"2020","unstructured":"Izgelov D, Davidson E, Barasch D, Regev A, Domb AJ, Hoffman A. Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers. Eur J Pharm Biopharm. 2020;154:108\u201315. https:\/\/doi.org\/10.1016\/j.ejpb.2020.06.021.","journal-title":"Eur J Pharm Biopharm"},{"key":"1380_CR20","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1021\/acs.molpharmaceut.0c00141","volume":"17","author":"D Izgelov","year":"2020","unstructured":"Izgelov D, Regev A, Domb AJ, Hoffman A. Using the absorption cocktail approach to assess differential absorption kinetics of cannabidiol administered in lipid-based vehicles in rats. Mol Pharm. 2020;17:1979\u201386. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00141.","journal-title":"Mol Pharm"},{"key":"1380_CR21","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1080\/17425247.2021.1952978","volume":"18","author":"\u00cdMDM Ramalho","year":"2021","unstructured":"Ramalho \u00cdMDM, Pereira DT, Galv\u00e3o GBL, Freire DT, Amaral-Machado L, Alencar \u00c9DN, Egito ESTD. Current trends on cannabidiol delivery systems: where are we and where are we going? Expert Opin Drug Del. 2021;18:1577\u201387. https:\/\/doi.org\/10.1080\/17425247.2021.1952978.","journal-title":"Expert Opin Drug Del"},{"key":"1380_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2147\/JPR.S240011","volume":"13","author":"MA \u00dcberall","year":"2020","unstructured":"\u00dcberall MA. A review of scientific evidence for THC:CBD oromucosal spray (nabiximols) in the management of chronic pain. J Pain Res. 2020;13:399\u2013410. https:\/\/doi.org\/10.2147\/JPR.S240011.","journal-title":"J Pain Res"},{"key":"1380_CR23","doi-asserted-by":"publisher","unstructured":"Martinez-Paz C, Garc\u00eda-Cabrera E, Vilches-Arenas A. Effectiveness and safety of cannabinoids as an add-on therapy in the treatment of resistant spasticity in multiple sclerosis: a systematic review. Cannabis Cannabinoid Res. 2023; in press. https:\/\/doi.org\/10.1089\/can.2022.0254.","DOI":"10.1089\/can.2022.0254"},{"key":"1380_CR24","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/phar.2512","volume":"41","author":"LH Siloramore","year":"2021","unstructured":"Siloramore LH, Willmer AR, Capparelli EV, Rosania GR. Food effects on the formulation, dosing, and administration of cannabidiol (CBD) in humans: a systematic review of clinical studies. Pharmacotherapy. 2021;41:405\u201320. https:\/\/doi.org\/10.1002\/phar.2512.","journal-title":"Pharmacotherapy"},{"key":"1380_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.5863\/1551-6776-25.1.75","volume":"25","author":"R Abu-Sawwa","year":"2020","unstructured":"Abu-Sawwa R, Stehling C. Epidiolex (cannabidiol) primer: frequently asked questions for patients and caregivers. J Pediatr Pharmacol Ther. 2020;25:75\u20137. https:\/\/doi.org\/10.5863\/1551-6776-25.1.75.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"1380_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph13090219","volume":"13","author":"SA Millar","year":"2020","unstructured":"Millar SA, Maguire RF, Yates AS, O\u2019Sullivan SE. Towards better delivery of cannabidiol (CBD). Pharmaceuticals. 2020;13:1\u201315. https:\/\/doi.org\/10.3390\/ph13090219.","journal-title":"Pharmaceuticals"},{"key":"1380_CR27","doi-asserted-by":"publisher","first-page":"122727","DOI":"10.1016\/j.ijpharm.2023.122727","volume":"635","author":"ER Lazzarotto Rebelatto","year":"2023","unstructured":"Lazzarotto Rebelatto ER, Schneider Rauber G, Caon T. An update of nano-based drug delivery systems for cannabinoids: Biopharmaceutical aspects & therapeutic applications. Int J Pharm. 2023;635:122727. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.122727.","journal-title":"Int J Pharm"},{"key":"1380_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/btm2.10143","volume":"4","author":"AC Anselmo","year":"2019","unstructured":"Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng Transl Med. 2019;4:1\u201316. https:\/\/doi.org\/10.1002\/btm2.10143.","journal-title":"Bioeng Transl Med."},{"key":"1380_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.addr.2018.09.001","volume":"131","author":"A Sosnik","year":"2018","unstructured":"Sosnik A, M\u00fchlebach S. Editorial: Drug nanoparticles and nano-cocrystals: from production and characterization to clinical translation. Adv Drug Deliver Rev. 2018;131:1\u20132. https:\/\/doi.org\/10.1016\/j.addr.2018.09.001.","journal-title":"Adv Drug Deliver Rev."},{"key":"1380_CR30","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.addr.2014.05.004","volume":"73","author":"A Sosnik","year":"2014","unstructured":"Sosnik A, Carcaboso AM. Nanomedicines in the future of pediatric therapy. Adv Drug Deliver Rev. 2014;73:140\u201361. https:\/\/doi.org\/10.1016\/j.addr.2014.05.004.","journal-title":"Adv Drug Deliver Rev."},{"key":"1380_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nano10071403","volume":"10","author":"B Begines","year":"2020","unstructured":"Begines B, Ortiz T, P\u00e9rez-Aranda M, Mart\u00ednez G, Merinero M, Arg\u00fcelles-Arias F, Alcudia A. Polymeric nanoparticles for drug delivery: Recent developments and future prospects. Nanomaterials. 2020;10:1\u201341. https:\/\/doi.org\/10.3390\/nano10071403.","journal-title":"Nanomaterials"},{"key":"1380_CR32","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.biotechadv.2015.01.003","volume":"33","author":"A Sosnik","year":"2015","unstructured":"Sosnik A, Menaker RM. Polymeric micelles in mucosal drug delivery: Challenges towards clinical translation. Biotechnol Adv. 2015;33:1380\u201392. https:\/\/doi.org\/10.1016\/j.biotechadv.2015.01.003.","journal-title":"Biotechnol Adv"},{"key":"1380_CR33","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1166\/jbn.2014.1887","volume":"10","author":"A Sosnik","year":"2014","unstructured":"Sosnik A. Production of drug-loaded polymeric nanoparticles by electrospraying technology. J Biomed Nanotechnol. 2014;10:2200\u201317. https:\/\/doi.org\/10.1166\/jbn.2014.1887.","journal-title":"J Biomed Nanotechnol"},{"key":"1380_CR34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cis.2015.05.003","volume":"223","author":"A Sosnik","year":"2015","unstructured":"Sosnik A, Seremeta KP. Advantages and challenges of the spray-drying technology for the production of pure drug particles and drug-loaded polymeric carriers. Adv Colloid Interface Sci. 2015;223:40\u201354. https:\/\/doi.org\/10.1016\/j.cis.2015.05.003.","journal-title":"Adv Colloid Interface Sci"},{"key":"1380_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jconrel.2011.09.064","volume":"158","author":"TK Dash","year":"2012","unstructured":"Dash TK, Konkimalla VB. Poly-\u03b5-caprolactone based formulations for drug delivery and tissue engineering: a review. J Control Release. 2012;158:15\u201333. https:\/\/doi.org\/10.1016\/j.jconrel.2011.09.064.","journal-title":"J Control Release"},{"key":"1380_CR36","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jcis.2008.03.033","volume":"322","author":"F Lince","year":"2008","unstructured":"Lince F, Marchisio DL, Barresi AA. Strategies to control the particle size distribution of poly-\u03b5-caprolactone nanoparticles for pharmaceutical applications. J Colloid Interface Sci. 2008;322:505\u201315. https:\/\/doi.org\/10.1016\/j.jcis.2008.03.033.","journal-title":"J Colloid Interface Sci"},{"key":"1380_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/polym14081509","author":"S Gottert","year":"2022","unstructured":"Gottert S, Salomatov R, Eder S, Seyfang B, Sotelo D, Osma J, Weiss C. Continuous nanoprecipitation of polycaprolactone in additively manufactured micromixers. Polymers. 2022. https:\/\/doi.org\/10.3390\/polym14081509.","journal-title":"Polymers"},{"key":"1380_CR38","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.2217\/NNM.13.167","volume":"9","author":"L Tshweu","year":"2014","unstructured":"Tshweu L, Katata L, Kalombo L, Chiappetta DA, Hocht C, Sosnik A, Swai H. Enhanced oral bioavailability of the antiretroviral efavirenz encapsulated in poly(epsilon-caprolactone) nanoparticles by a spray-drying method. Nanomedicine. 2014;9:1821\u201333. https:\/\/doi.org\/10.2217\/NNM.13.167.","journal-title":"Nanomedicine"},{"key":"1380_CR39","doi-asserted-by":"publisher","first-page":"39633","DOI":"10.1021\/acsami.9b14659","volume":"11","author":"N Kuplennik","year":"2019","unstructured":"Kuplennik N, Lang K, Steinfeld R, Sosnik A. Folate receptor \u03b1-modified nanoparticles for targeting of the central nervous system. ACS Appl Mater Interfaces. 2019;11:39633\u201347. https:\/\/doi.org\/10.1021\/acsami.9b14659.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1380_CR40","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/jbm.a.32247","volume":"91","author":"T Betancourt","year":"2009","unstructured":"Betancourt T, Byrne JD, Sunaryo N, Crowder SW, Kadapakkam M, Patel S, Casciato S, Brannon-Peppas L. PEGylation strategies for active targeting of PLA\/PLGA nanoparticles. J Biomed Mater Res Part A. 2009;91:263\u201376. https:\/\/doi.org\/10.1002\/jbm.a.32247.","journal-title":"J Biomed Mater Res Part A"},{"key":"1380_CR41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jconrel.2017.05.028","volume":"260","author":"P Grossen","year":"2017","unstructured":"Grossen P, Witzigmann D, Sieber S, Huwyler J. PEG-PCL-based nanomedicines: a biodegradable drug delivery system and its application. J Control Release. 2017;260:46\u201360. https:\/\/doi.org\/10.1016\/j.jconrel.2017.05.028.","journal-title":"J Control Release"},{"key":"1380_CR42","doi-asserted-by":"publisher","first-page":"122901","DOI":"10.1016\/j.polymer.2020.122901","volume":"207","author":"A Behl","year":"2020","unstructured":"Behl A, Parmar VS, Malhotra S, Chhillar AK. Biodegradable diblock copolymeric PEG-PCL nanoparticles: Synthesis, characterization and applications as anticancer drug delivery agents. Polymer. 2020;207:122901. https:\/\/doi.org\/10.1016\/j.polymer.2020.122901.","journal-title":"Polymer"},{"key":"1380_CR43","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.msec.2016.04.001","volume":"66","author":"M Eltayeb","year":"2016","unstructured":"Eltayeb M, Stride E, Edirisinghe M, Harker A. Electrosprayed nanoparticle delivery system for controlled release. Mater Sci Eng C. 2016;66:138\u201346. https:\/\/doi.org\/10.1016\/j.msec.2016.04.001.","journal-title":"Mater Sci Eng C"},{"key":"1380_CR44","doi-asserted-by":"publisher","first-page":"121336","DOI":"10.1016\/j.talanta.2020.121336","volume":"219","author":"P Berman","year":"2020","unstructured":"Berman P, Sulimani L, Gelfand A, Amsalem K, Lewitus GM, Meiri D. Cannabinoidomics \u2013 An analytical approach to understand the effect of medical Cannabis treatment on the endocannabinoid metabolome. Talanta. 2020;219:121336. https:\/\/doi.org\/10.1016\/j.talanta.2020.121336.","journal-title":"Talanta"},{"issue":"3","key":"1380_CR45","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","volume":"99","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99(3):306\u201314. https:\/\/doi.org\/10.1016\/j.cmpb.2010.01.007.","journal-title":"Comput Methods Programs Biomed"},{"key":"1380_CR46","doi-asserted-by":"publisher","first-page":"7033","DOI":"10.1016\/j.polymer.2003.09.012","volume":"44","author":"A Sosnik","year":"2003","unstructured":"Sosnik A, Cohn D. Poly(ethylene glycol)-poly(epsilon-caprolactone) block oligomers as injectable materials. Polymer. 2003;44:7033\u201342. https:\/\/doi.org\/10.1016\/j.polymer.2003.09.012.","journal-title":"Polymer"},{"key":"1380_CR47","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jconrel.2017.04.016","volume":"255","author":"C Monterrubio","year":"2017","unstructured":"Monterrubio C, Paco S, Olaciregui NG, Pascual-Pasto G, Vila-Ubach M, Cuadrado-Vilanova M, Ferrandiz MM, Castillo-Ecija H, Glisoni R, Kuplennik N, Jungbluth A, de Torres C, Lavarino C, Cheung NKV, Mora J, Sosnik A, Carcaboso AM. Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8. J Control Release. 2017;255:108\u201319. https:\/\/doi.org\/10.1016\/j.jconrel.2017.04.016.","journal-title":"J Control Release"},{"key":"1380_CR48","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1517\/17425247.2015.1018175","volume":"12","author":"EM Pridgen","year":"2015","unstructured":"Pridgen EM, Alexis F, Farokhzad OC. Polymeric nanoparticle drug delivery technologies for oral delivery applications. Expert Opin Drug Deliv. 2015;12:1459\u201373. https:\/\/doi.org\/10.1517\/17425247.2015.1018175.","journal-title":"Expert Opin Drug Deliv"},{"key":"1380_CR49","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jconrel.2016.06.016","volume":"240","author":"AA Date","year":"2016","unstructured":"Date AA, Hanes J, Ensign LM. Nanoparticles for oral delivery: Design, evaluation and state-of-the-art. J Control Release. 2016;240:504\u201326. https:\/\/doi.org\/10.1016\/j.jconrel.2016.06.016.","journal-title":"J Control Release"},{"key":"1380_CR50","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ejpb.2021.05.024","volume":"165","author":"E Trenkenschuh","year":"2021","unstructured":"Trenkenschuh E, Friess W. Freeze-drying of nanoparticles: How to overcome colloidal instability by formulation and process optimization. Eur J Pharm Biopharm. 2021;165:345\u201360. https:\/\/doi.org\/10.1016\/j.ejpb.2021.05.024.","journal-title":"Eur J Pharm Biopharm"},{"key":"1380_CR51","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ijpharm.2009.11.035","volume":"387","author":"M Messner","year":"2010","unstructured":"Messner M, Kurkov SV, Jansook P, Loftsson T. Self-assembled cyclodextrin aggregates and nanoparticles. Int J Pharm. 2010;387:199\u2013208. https:\/\/doi.org\/10.1016\/j.ijpharm.2009.11.035.","journal-title":"Int J Pharm"},{"key":"1380_CR52","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1098\/rsif.2011.0414","volume":"9","author":"MA Moretton","year":"2012","unstructured":"Moretton MA, Chiappetta DA, Sosnik A. Cryoprotection-lyophilization and physical stabilization of rifampicin-loaded flower-like polymeric micelles. J R Soc Interface. 2012;9:487\u2013502. https:\/\/doi.org\/10.1098\/rsif.2011.0414.","journal-title":"J R Soc Interface"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-023-01380-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-023-01380-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-023-01380-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T18:09:09Z","timestamp":1699034949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-023-01380-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":52,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1380"],"URL":"https:\/\/doi.org\/10.1007\/s13346-023-01380-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2962018\/v1","asserted-by":"object"}]},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"assertion":[{"value":"13 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal studies have been conducted under the ethical guidelines of animal experimentation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and agreed to the published version of the review manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}